Will the clinical development of 4th-generation “double mutant active” ALK TKIs (TPX-0131 and NVL-655) change the future treatment paradigm of ALK+ NSCLC?-Reference-Cited by-同舟云学术

Will the clinical development of 4th-generation “double mutant active” ALK TKIs (TPX-0131 and NVL-655) change the future treatment paradigm of ALK+ NSCLC?

Published:2021-11 Issue:11 Volume:14 Page:101191
ISSN:1936-5233
Container-title:Translational Oncology
language:en
Short-container-title:Translational Oncology

Author:

Ou Sai-Hong Ignatius,Nagasaka Misako,Brazel Danielle,Hou Yujie,Zhu Viola W.

Funder

Takeda Pharmaceuticals U.S.A.

Publisher

Elsevier BV

Subject

Cancer Research,Oncology

Reference55 articles.

1. Lorlatinib should be considered as the preferred first-line option in patients with advanced ALK-rearranged NSCLC;Nagasaka;J. Thorac. Oncol.,2021

2. First-line crizotinib versus chemotherapy in ALK-positive lung cancer;Solomon;N. Engl. J. Med.,2014

3. Final overall survival analysis from a study comparing first-line crizotinib versus chemotherapy in ALK-mutation-positive non-small-cell lung cancer;Solomon;J. Clin. Oncol.,2018

4. Results of PROFILE 1029, a Phase III Comparison of First-Line Crizotinib versus chemotherapy in East Asian patients with ALK-positive advanced non-small cell lung cancer;Wu;J. Thorac. Oncol.,2018

5. First-line ceritinib versus platinum-based chemotherapy in advanced ALK-rearranged non-small-cell lung cancer (ASCEND-4): a randomized, open-label, phase 3 study;Soria;Lancet,2017

Cited by 25 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. An ultra‐fast green ultra‐high‐performance liquid chromatography‐tandem mass spectrometry method for estimating the in vitro metabolic stability of zotizalkib in human liver microsomes;Journal of Separation Science;2024-08

2. Promoting reactive oxygen species accumulation to overcome tyrosine kinase inhibitor resistance in cancer;Cancer Cell International;2024-07-09

3. Insight into systematic development of ALK (anaplastic lymphoma kinase) inhibitors towards NSCLC treatment;European Journal of Medicinal Chemistry Reports;2024-04

4. Developments in predictive biomarker testing and targeted therapy in advanced stage non-small cell lung cancer and their application across European countries;The Lancet Regional Health - Europe;2024-03

5. Overcoming Central β-Sheet #6 (Cβ6) ALK Mutation (L1256F), TP53 Mutations and Short Forms of EML4-ALK v3/b and v5a/b Splice Variants are the Unmet Need That a Re-Imagined 5th-Generation (5G) ALK TKI Must Deliver;Lung Cancer: Targets and Therapy;2024-02